This company has been marked as potentially delisted and may not be actively trading. Checkmate Pharmaceuticals (CMPI) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CMPI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Axonis Therapeutics Announces $115 Million Series A FinancingOctober 31, 2024 | finance.yahoo.comvenBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesAugust 1, 2024 | finance.yahoo.comCheckmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Short Interest UpdateMay 30, 2022 | marketbeat.comCheckmate Pharmaceuticals (Nasdaq:CMPI) HeadlineTrading was temporarily halted for "CMPI" at 07:05 PM with a stated reason of "News pending."...May 30, 2022 | marketbeat.comUniversity of Iowa Holden Comprehensive Cancer Center PresentsMay 26, 2022 | tmcnet.comUniversity of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingMay 26, 2022 | finance.yahoo.com Analysts Expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) to Post -$0.75 Earnings Per ShareMay 20, 2022 | marketbeat.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates TVTY, ACC, SWCH, CMPIMay 18, 2022 | apnews.comACheckmate Pharmaceuticals GAAP EPS of -$0.73 beats by $0.02May 13, 2022 | seekingalpha.comCheckmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 13, 2022 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates NLSN, CMPI, SBOWMay 5, 2022 | apnews.comA-$0.73 EPS Expected for Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) This QuarterApril 29, 2022 | marketbeat.comCheckmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Global Strategic Fund I. Venbio Sells 47,396 SharesApril 29, 2022 | marketbeat.comRegeneron (REGN) to Buy Checkmate Pharmaceuticals for $250MApril 20, 2022 | msn.comShareholder Alert: Ademi LLP investigates whether Checkmate Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with RegeneronApril 20, 2022 | barrons.comCheckmate stock quadruples on news of Regenerate acquisitionApril 19, 2022 | bizjournals.comWhy Checkmate Pharmaceuticals Stock Is Rocketing Higher TodayApril 19, 2022 | finance.yahoo.comCMPI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Checkmate Pharmaceuticals, Inc. Is Fair to ShareholdersApril 19, 2022 | stockhouse.comCheckmate Pharmaceuticals Shares Take Flight on Regeneron Deal >CMPIApril 19, 2022 | marketwatch.comCheckmate Pharmaceuticals (Nasdaq:CMPI) HeadlineTrading was temporarily halted for "CMPI" at 07:04 AM with a stated reason of "News pending."...April 19, 2022 | marketbeat.comCheckmate Pharmaceuticals Presents Clinical Trial Biomarker Data withApril 8, 2022 | tmcnet.comCheckmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual MeetingApril 8, 2022 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 8, 2022 | nz.finance.yahoo.comCheckmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 8, 2022 | finance.yahoo.comThe Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars gameFebruary 10, 2022 | bizjournals.comCheckmate Pharmaceuticals appoints Alan Bash as President, CEOFebruary 9, 2022 | seekingalpha.comCheckmate Pharmaceuticals Appoints Alan Bash as President and CEOFebruary 9, 2022 | finance.yahoo.comCheckmate Pharmaceuticals, Inc. Common Stock (CMPI)January 31, 2022 | nasdaq.comCheckmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of DirectorsJanuary 31, 2022 | finance.yahoo.comHere's Why We're A Bit Worried About Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn SituationJanuary 7, 2022 | nasdaq.comCheckmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceJanuary 3, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using VidutolimodDecember 20, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 15, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingNovember 12, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business UpdateNovember 12, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceNovember 11, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingNovember 1, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces CEO TransitionOctober 27, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)October 20, 2021 | finance.yahoo.comWe're Keeping An Eye On Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn RateOctober 13, 2021 | finance.yahoo.comOne Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) insider upped their stake by 2.5% in the previous yearOctober 9, 2021 | nasdaq.comWhy BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price TargetOctober 6, 2021 | markets.businessinsider.comCheckmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare ConferenceSeptember 14, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceSeptember 7, 2021 | finance.yahoo.comPeek Under The Hood: VTI Has 11% UpsideAugust 21, 2021 | nasdaq.comCheckmate Pharmaceuticals Inc.August 12, 2021 | barrons.comCheckmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business UpdateAugust 12, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology ConferenceAugust 2, 2021 | finance.yahoo.com Get Checkmate Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPI and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPI Media Mentions By Week CMPI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPI News Sentiment▼0.000.54▲Average Medical News Sentiment CMPI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPI Articles This Week▼00▲CMPI Articles Average Week Get Checkmate Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prime Medicine News Today Protalix BioTherapeutics News Today Inhibikase Therapeutics News Today ZIVO Bioscience News Today CEL-SCI News Today Invizyne Technologies News Today Cortexyme News Today AlloVir News Today NKGen Biotech News Today Calidi Biotherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPI) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkmate Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkmate Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access